Printer Friendly
The Free Library
19,604,538 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cellegy Announces Third Quarter Results.


FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 4, 1996--Cellegy Pharmaceuticals Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:CLGY, Warrants:CLGYW) today announced that for the third quarter ended Sept. 30, 1996, the company had a net loss of $894,000, or $0.20 per share, compared with a net loss of $884,000, or $0.27 per share, for the same period last year.

For the nine months ended Sept. 30, 1996, the company had a net loss of $2,750,000, or $0.68 per share, on revenues of $15,000, compared with a net loss of $1,243,000, or $0.41 per share, on revenues of $1,000,000, for the nine months ended Sept. 30, 1995.

Revenues in 1995 resulted from the company's licensing arrangement with Neutrogena This article or section is written like an .
Please help [ rewrite this article] from a neutral point of view.
Mark blatant advertising for , using .
 Corp., a subsidiary of Johnson & Johnson. Cash, cash equivalents and short-term Short-term

Any investments with a maturity of one year or less.


short-term

1. Of or relating to a gain or loss on the value of an asset that has been held less than a specified period of time.
 investments at Sept. 30, 1996, were approximately ap·prox·i·mate  
adj.
1. Almost exact or correct: the approximate time of the accident.

2.
 $7.5 million.

On Oct. 17, 1996, the company announced that it had signed a Letter of Intent with Glaxo Wellcome This article is about the supermarket chain. For the pharmaceutical entrepreneur, see Henry Wellcome. For the charity and related companies, see Wellcome Trust.

Wellcome (Chinese: 惠康 
 Inc. for the licensing of Glylorin(TM). Cellegy is in the process of finalizing the definitive agreement, which it believes will strengthen the company's cash position, lower its research and development costs associated with Glylorin development funding, which will be assumed by Glaxo, and result in certain near term contract revenues.

Cellegy is currently in active discussions with a number of other potential corporate partners for the development and licensing of its products. Although there can be no assurance that these discussions will result in definitive agreements, these partnerships, once completed, could be a potential source of significant future revenue.

Cellegy is a pharmaceutical company engaged in the development, through corporate collaborations and marketing arrangements, of innovative drug delivery products as well as consumer and prescription prescription

In property law, the effect of the lapse of time in creating and destroying rights. Acquisitive prescription allows an individual, after unequivocal possession for a specific period, to acquire an interest in real property, such as an easement, but not the
 products for the skin. -0-
                     Cellegy Pharmaceuticals Inc.
                      Summary Financial Results

                  Condensed Statements of Operations
           (Amounts in Thousands, except per share amounts)


                              Three Months Ended   Nine Months Ended
                                    Sept. 30,           Sept. 30,
                                 1996      1995      1996      1995

Revenues                      $   ---   $   ---   $    15   $ 1,000
Operating and other income
 (expenses)                   $  (894)  $  (884)  $(2,765)  $(2,243)
   Net income (loss)          $  (894)  $  (884)  $(2,750)  $(1,243)
   Net income (loss) per
    share                     $ (0.20)  $ (0.27)  $ (0.68)  $ (0.41)


                      Condensed Balance Sheets
                       (Amounts in thousands)

                                       Sept. 30, 1996    Dec. 31, 1995

Cash, cash equivalents & short term
 investments                                $7,505           $3,820
Other assets                                $  356           $  208
   Total Assets                             $7,861           $4,028
Payables and accrued liabilities            $  160           $  380
Shareholders' equity                        $7,701           $3,648
   Total liabilities and shareholders'
    equity                                  $7,861           $4,028




CONTACT: Cellegy Pharmaceuticals Inc.

A. Richard Ri·chard   , Joseph Henri Maurice Known as "Rocket." 1921-2000.

Canadian hockey player. A right wing for the Montreal Canadiens (1942-1960), he led his team to eight Stanley Cup championships and was the first player to score 50 goals in a
 Juelis, 415/524/1600 (company)

or

Jimmy Caplan Caplan may refer to:

person:
  • Arthur Caplan, American bioethicist
  • Bryan Caplan (b. 1971), American economist
  • David Caplan (b. 1964), Canadian politician
  • Elinor Caplan (b. 1944 ), Canadian politician
  • Gerald Caplan (b.
, 805/569-0076 (investor)

or

Rick Eisenberg Eisenberg can refer to:
  • places in Germany:
  • Eisenberg, Thuringia, a town in the Saale-Holzland district, Thuringia.
, 212/496-6828 (investor)
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 4, 1996
Words:439
Previous Article:Berkeley Systems Ships Star-Studded You Don't Know Jack Volume 2; It's Time To Find Out That YOU still DON'T KNOW JACK.
Next Article:SDRC to strengthen company business and operations functions by filling a key management post.
Topics:



Related Articles
Cellegy receives FDA grant to test skin disease treatment.
Cellegy Pharmaceuticals announces the appointment of Coffin Communications Group as investor-relations agent.
Cellegy Pharmaceuticals reports first quarter financial results.
Cellegy Pharmaceuticals Completes a $3.8 Million Private Placement and Reacquires Rights to Patented Skin Repair Technology.
Cellegy Pharmaceuticals Reports Third Quarter Financial Results.
Cellegy Pharmaceuticals and PanGeo Pharma Announce Supply Agreement for Tostrex --TM--.
Cellegy Selects QUMAS DocCompliance to Manage Regulatory and Clinical Documentation.
Insignia Financial Group Inc. releases third quarter results.
Dutton Associates Announces Investment Opinion: Cellegy Pharmaceuticals Raised to Speculative Buy Rating by Dutton Associates.
Who's Developing What in Drug Delivery 2005?

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles